Opdivo Outperforms Taxotere in lung cancer drug trials
September 14, 2017
In results recently presented at a meeting in Madrid of the European Society for Medical Oncology (ESMO), researchers from the Val d’Hebron University Hospital in Spain showed that the drug Opdivo has outperformed controversial chemotherapy drug Taxotere in a three-year clinical trial of advanced and earlier treated lung cancers. Survival rates with Opdivo were more than twice those of Taxotere.
The trial included 582 patients, took place over more than 36 months, and involved patients with squamous non-cell lung cancer (NSCLC). After the term of the trial, 16 percent of Opdivo patients remained alive; only six percent of Taxotere patients were alive.
The findings are significant not just because they suggest a more successful course of treatment for patients with NSCLC, but because Taxotere has been linked to other serious side effects, for which its manufacturer, the multinational pharmaceutical corporation Sanofi-Aventis, has been taken to trial in numerous lawsuits.
Taxotere, a chemotherapy drug that is often used to treat breast cancer, is alleged by thousands of female patients to cause permanent post-treatment hair loss.
The ESMO study does not remark on Opdivo as a substitute for Taxotere in breast cancer treatment.
If you’ve been given Taxotere as a breast cancer treatment, and have suffered from permanent hair loss as a result, you may wish to file a lawsuit. At TheLawFirm.com, we believe that your health is more important than corporate profits, and we’d be honored to take your case. Contact us today for a free consultation.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!